hydroxyurea has been researched along with Neglected Diseases in 2 studies
Neglected Diseases: Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa." | 2.90 | Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. ( Aygun, B; Lane, A; Latham, TS; McGann, PT; Olupot-Olupot, P; Santos, B; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darshana, T | 1 |
| Rees, D | 1 |
| Premawardhena, A | 1 |
| Tshilolo, L | 1 |
| Tomlinson, G | 1 |
| Williams, TN | 1 |
| Santos, B | 1 |
| Olupot-Olupot, P | 1 |
| Lane, A | 1 |
| Aygun, B | 1 |
| Stuber, SE | 1 |
| Latham, TS | 1 |
| McGann, PT | 1 |
| Ware, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731] | Phase 1/Phase 2 | 635 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hydroxyurea | 5.1 |
1 review available for hydroxyurea and Neglected Diseases
| Article | Year |
|---|---|
Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.
Topics: Anemia, Sickle Cell; Bangladesh; Blood Transfusion; Humans; Hydroxyurea; India; Neglected Diseases; | 2021 |
1 trial available for hydroxyurea and Neglected Diseases
| Article | Year |
|---|---|
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose- | 2019 |